<DOC>
	<DOC>NCT01170962</DOC>
	<brief_summary>The purpose of this study is to determine whether BMS-790052 added to Peginterferon Alfa-2a and ribavirin can result in higher cure rates in patients who previously failed therapy and may have limited response to retreatment with Peginterferon Alfa-2a and ribavirin alone.</brief_summary>
	<brief_title>Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Subjects chronically infected with HCV genotype 1 Nonresponder to prior therapy with peginterferon alfa and ribavirin HCV RNA viral load of 100,00 IU/mL Results of a liver biopsy â‰¤ 24 months prior to randomization consistent with chronic HCV infection; for compensated cirrhotics can be any time prior to randomization (compensated cirrhotics biopsy enrollment will be capped at 25% of randomized study population) Ultrasound, CT scan or MRI results 12 months prior to randomization that do not demonstrate hepatocellular carcinoma Body Mass Index (BMI) of 18 to 35 kg/m2 Positive for Hepatitis B infection (HBsAg) or HIV1/HIV2 antibody at screening Evidence of medical condition associated with chronic liver disease other than HCV Evidence of decompensated cirrhosis based on radiologic criteria or biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>